 W e are a fast growing specialist healthcare  
company , headquartered in London and  
employing over 1 , 1 00 people worldwide. 
W e operate in three discrete business segments: 
Interventional Medicine (IM) ( oncology , vascular and 
pulmonology products ), Specialty Pharmaceuticals 
(antidote products ) and Licensing (royalties from 
licensed assets ).
Business segments
Medical discipline Product Medical use Geographic  
availability
Interventional Medicine
Read more on page 24
Oncology Beads Liver tumours US, EU, Asia
TheraSphere
®
Liver tumours US, EU, Asia
Vascular EkoSonic
®
Severe blood clots US, EU
Varithena
®
Moderate to severe  
varicose veins
US
Pulmonology RePneu
® 
Coil Emphysema US, EU, Asia
Specialty 
Pharmaceuticals
Read more on page 25
Acute care,  
antidote 
products
CroFab
®
Crotalid snakebites US
DigiFab
®
Digoxin toxicity US, EU, Aus
Voraxaze
®
High-dose methotrexate 
toxicity
US, EU
Licensing
Read more on page 25
Royalties from 
out-licensed 
intellectual 
property
Abiraterone acetate 
(Zytiga
®
)
Advanced prostate cancer Global
Alemtuzumab 
(Lemtrada
™
)
Multiple sclerosis Global
T wo-Part Hip Cup Hip replacement Global
02
Strategic 
Report
BTG plc Annual Report and Accounts 201 5
BTG at a glance
